STX Share Price Performance
UK£0.067
0.04 (148.15%)
58.1% undervalued intrinsic discount
UK£0.16
Fair Value
Price UK£0.067
AnalystConsensusTarget UK£0.16
AnalystHighTarget UK£0.23
AnalystLowTarget UK£0.032
Fair ValueUK£0.16
Share Pricen/a
Shield Therapeutics plc Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 20 Fair Values set on narratives written by author
STX Community Narratives
AN
Fair Value UK£0.16 58.1% undervalued intrinsic discount
Analysts Maintain Target for Shield Therapeutics Amid Positive Clinical News and Stable Valuation Metrics
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
Fair Value UK£0.23 70.9% undervalued intrinsic discount
Digital Marketing And Oral Iron Therapy Will Drive Adoption
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value UK£0.032 109.4% overvalued intrinsic discount
Single Asset Dependency And US Pricing Challenges Will Mar Prospects
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Analysts Maintain Target for Shield Therapeutics Amid Positive Clinical News and Stable Valuation Metrics
Key Takeaways An expanding addressable market and greater screening activity are driving strong prescription growth and recurring revenues for Shield's main product. Strategic partnerships, international expansion, and improved operational efficiency are positioned to enhance margins and drive sustained profit growth.Read more
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
UK£0.16
58.1% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
41.83% p.a.
Profit Margin
24.86%
Future PE
9x
Share price in 2028
UK£0.19
Digital Marketing And Oral Iron Therapy Will Drive Adoption
Key Takeaways Accelerated digital and influencer marketing, alongside oral-first therapies, could significantly expand market share and net margins beyond current analyst expectations. Strategic geographic launches, pending label expansions, and targeted product acquisitions set the stage for compounded growth and multi-product profitability.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
UK£0.23
70.9% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
65.35% p.a.
Profit Margin
27.53%
Future PE
7.65x
Share price in 2028
UK£0.28
Single Asset Dependency And US Pricing Challenges Will Mar Prospects
Key Takeaways Dependence on a single product and increasing generic competition heighten vulnerability to revenue loss and market share erosion. Pricing pressures, restrictive reimbursement, and rising regulatory demands threaten margin sustainability and long-term profitability.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
UK£0.032
109.4% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
38.39% p.a.
Profit Margin
46.31%
Future PE
1.07x
Share price in 2028
UK£0.037
Snowflake Analysis
Shield Therapeutics plc Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.02
- 48.34%
- -51.18%
- -181.4%
About STX
- Founded
- 2008
- Employees
- 63
- CEO
- WebsiteView website
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.
